What Researchers Did
Researchers ran randomised trials over 12 years at Portsmouth, England, comparing survival in cancer patients given megavoltage radiotherapy in high pressure oxygen with patients given the same type of radiotherapy in air.
What They Found
This set of randomised trials of radiotherapy in high pressure oxygen included 505 patients and found that, with conventional small daily fractions, high pressure oxygen did not improve survival in bronchus or bladder cancer. The patients had carcinoma of the bronchus (280), carcinoma of the bladder (163) or stage III carcinoma of the cervix (62). When six fractions of 600 rad maximum tissue dose were given in high pressure oxygen, the abstract reports some improved survival in bronchus and cervix cancer compared with the same dose given in air. In the cervix group, survival with high pressure oxygen was almost the same as in a retrospective series treated with an intrauterine radium tube followed by 6000 rad in air. Large fraction radiotherapy with high pressure oxygen did not improve survival in bladder cancer, and the bladder trial was abandoned.
What This Means for Canadian Patients
For people with bronchus, bladder or cervix cancer, this study found no survival gain from high pressure oxygen with conventional daily radiotherapy in bronchus or bladder cancer. The survival gains with the six-fraction schedule were described only as "some" improvement in bronchus and cervix cancer, and the bladder trial with large fractions showed no benefit. The abstract does not say how these findings apply to current treatment, so patients should discuss options with their cancer care team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract gives no statistical tests for the survival differences, and the cervix comparison with the radium series was against a retrospective group rather than a randomised one.